MEO, Anna
 Distribuzione geografica
Continente #
NA - Nord America 1.010
EU - Europa 821
AS - Asia 196
OC - Oceania 4
SA - Sud America 3
Totale 2.034
Nazione #
US - Stati Uniti d'America 1.007
IE - Irlanda 241
SE - Svezia 232
CN - Cina 150
UA - Ucraina 113
DE - Germania 77
FI - Finlandia 39
GB - Regno Unito 39
IT - Italia 35
IR - Iran 21
BE - Belgio 16
SG - Singapore 11
RU - Federazione Russa 8
FR - Francia 6
CA - Canada 3
IL - Israele 3
PL - Polonia 3
AU - Australia 2
BG - Bulgaria 2
CZ - Repubblica Ceca 2
ES - Italia 2
IN - India 2
JP - Giappone 2
NL - Olanda 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
BR - Brasile 1
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
ID - Indonesia 1
KR - Corea 1
LI - Liechtenstein 1
MY - Malesia 1
OM - Oman 1
PK - Pakistan 1
SA - Arabia Saudita 1
TR - Turchia 1
Totale 2.034
Città #
Dublin 240
Jacksonville 213
Chandler 187
Nyköping 137
Beijing 85
Ann Arbor 52
Ashburn 46
New York 41
Cambridge 40
Princeton 36
Medford 32
Des Moines 28
Boardman 27
Woodbridge 22
Tehran 21
Brussels 16
Dearborn 15
Jinan 12
Houston 11
Wilmington 11
Lancaster 9
Nanjing 9
Seattle 8
Shenyang 8
Auburn Hills 7
Bremen 7
Tianjin 7
Los Angeles 5
Messina 5
San Mateo 5
Singapore 5
Turin 5
Washington 5
Changsha 4
Helsinki 4
Kiev 4
Rome 4
Fuzhou 3
Hebei 3
Phoenix 3
Pittsburgh 3
Pound Ridge 3
Catania 2
Erfurt 2
Fairfield 2
Florence 2
Guangzhou 2
Hangzhou 2
Hyderabad 2
Jiaxing 2
Munich 2
Nanchang 2
Sofia 2
Taiyuan 2
Taizhou 2
Tokyo 2
Torino 2
Warsaw 2
Amsterdam 1
Anchorage 1
Auckland 1
Augusta 1
Bari 1
Bricherasio 1
Brno 1
Clearwater 1
Copenhagen 1
Cupertino 1
Denver 1
Edinburgh 1
Flumeri 1
Freiburg 1
Gießen 1
Granada 1
Jeffries 1
Jundiaí 1
Kuantan 1
Kunming 1
Lanzhou 1
Leawood 1
Madrid 1
Milan 1
Montreal 1
Muscat 1
Ningbo 1
Norwalk 1
Pabianice 1
Paris 1
Pereira 1
Perth 1
Reading 1
Saint Petersburg 1
Schwäbisch Gmünd 1
Seoul 1
Seregno 1
Southwell 1
Strasbourg 1
Sydney 1
Tappahannock 1
Tel Aviv 1
Totale 1.462
Nome #
Bisphosphonates in the treatment of thalassemia-associated osteoporosis. 85
Hepcidin mutation in a beta-thalassemia major patient with persistent severe iron overload despite chelation therapy. 80
Serum levels of interleukin-18 in splenectomized and nonsplenectomized thalassemic patients: preliminary considerations. 76
Role of genetic pattern on bone mineral density in thalassemic patients 75
null 74
Valutazione del ferro non legato alla transferrina NTBI in soggetti affetti dalla beta talassemia trattati con terapia ferrochelante combinata(desferrioxamina+deferiprone)o con monoterapia(desferrioxamina o deferiprone) 69
Asymptomatic cholelithiasis in children with sickle cell disease: early or delayed cholecystectomy? 68
Serum pro-hepcidin and iron status in thalassaemia. Haematologica 65
Fertility and reproduction in thalassaemia major. 65
Serum Pro-hepcidin and iron status in Thalassaemia Major (TM) and Thalassaemia Intermedia (TI) patients. 62
Iron overload and NTBI monitorino after bone marrow transplantation 62
Three-year prospective evaluation of glucose tolerance, beta- cell function and peripheral insulin sensitivity in non- diabetic patients with thalassemia major 62
Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases 60
Bisphosphonates in the treatment of thalassemia-induced osteoporosis 60
Long-term treatment with deferiprone in a L1 veteran. 59
Laparoscopic cholecystectomy in children with beta-thalassemia major and asyntomatic cholelithiasis 58
Osteoporosis and beta-thalassemia major: Role of the IGF- I/IGFBP-III axis 58
Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation 58
Molecular analysis of beta-thalassaemia patients in a high incidence area of southern Italy. 58
Prevalence of TTV-DNA in blood samples from healthy subjects, microcytic anaemia sufferers, dialysis patients and kidney-transplant (former dialysis) patients in the city of Messina. 57
Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review. 57
Il trapianto di midollo osseo allogenico nella talassemia 55
Qualità della vita nei talassemici dopo trapianto di midollo osseo 54
Pregnancy in Patients with Beta-Thalassaemia Major: Maternal and Foetal Outcome. 50
Glucose tolerance, insulin secretion and peripheral sensitivity in thalassaemia major 50
The "lively" cytokines network in beta-Thalassemia Major-related osteoporosis. 49
The almond milk: a new approach to the management of cow-milk allergy/intolerance in infants. 49
Gene symbol: HAMP. Disease: Haemochromatosis, juvenile mio 46
SQUID biosusceptometry in hematological diseases 44
Ten year follow-up in hereditary sideroblastic anemia (HSA) after bone marrow transplantation (BMT): how a net negative iron balance has been reached. 44
Role of polymorphic sequences 5 ' to the (G)gamma gene and 5 ' to the beta gene on the homozygous beta thalassemic phenotype 43
The Spectrum of -Thalassemia in the Western Sicily. Blood 39
Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: New pieces of the puzzle 39
Trasporto anionico negli eritrociti dei pazienti talassemici splenectomizzati e non 38
Validation of DHPLC for molecular diagnosis of beta-thalassemia in southern Italy 37
Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. 29
Studio prospettico triennale della tolleranza glucidica , della funzione beta cellulare e della sensibilità periferica all’insulina in pazienti non diabetici con Thalassemia Major 27
Totale 2.061
Categoria #
all - tutte 7.325
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.325


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020291 0 29 4 28 1 17 45 37 3 65 58 4
2020/2021211 35 1 54 8 5 32 4 28 1 26 8 9
2021/2022263 3 43 11 7 6 1 14 8 10 59 29 72
2022/2023749 50 80 41 52 61 75 5 40 315 5 21 4
2023/2024197 8 43 1 14 18 56 1 14 1 7 5 29
2024/202513 10 3 0 0 0 0 0 0 0 0 0 0
Totale 2.061